This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-012054-bpgb7tgo | How good is fluorine as a hydrogen bond acceptor? |
| cord-002561-7j43yic1 | Novel human astroviruses: Novel human diseases? |
| cord-255137-utg8k7qs | The ascension of wildlife rabies: a cause for public health concern or intervention? |
| cord-005057-deq5tv1d | Functional and molecular analyses of the avirulent wild- type herpes simplex virus type 1 strain KOS Induction of demyelination by a temperature- sensitive mutant of the coronavirus MHV- A59 is associated with restriction of viral replication in the brain Can a defectwc herpes simplex virus cause multiple sclerosis? |
| cord-296611-ma32oz4o | Why do RNA viruses recombine? |
| cord-010641-hk90qx1k | Mycobacterium bovis BCG alter global gene expression without attenuating growth Analysis of global transcriptional profiles of enterotoxigenic Escherichia coli isolate E24377A Regulated proteolysis in gramnegative bacteria- how and when? |
| cord-018061-jy3km0fr | Enhance or Inhibit Viral Gastroenteritis? cord-022383-pz0htccp Excre tion and transmission of virus occurs via the respiratory tract( Jacoby |
| cord-008777-i2reanan | Extending life by alternative respiration? |
| cord-008777-i2reanan | For example, one of the often asked questions is:"What is happening with shorter cellooligosacharides( DP 7 and up) laying on the surface of cellulose chain? |
| cord-008777-i2reanan | In order to further substantiate the potential use of siRNA for therapeutic purposes, we have set out to investigate two things:( 1) Does VCAM-1-specific siRNA affect the amount of VCAM-1 on the surface of HUVEC? |
| cord-008777-i2reanan | Is this realistic? |
| cord-008777-i2reanan | Two days of open discussions were organized in the context of the Austrian Genome Research Program GEN- AU( 3): topics were"Gene Diagnosis"( 2002) and"Genome Research- what is in it for me?"( 2004). |
| cord-008777-i2reanan | Will we switch from a petrochemical industry to a biobased chemistry within the next years? |
| cord-007890-bie1veti | ( 5?-GCAAGTTCTT- CAGCTTGTTT-3?). |
| cord-007890-bie1veti | ( 5?-TATTGCGCT- TAGAAAATTAA-3?) |
| cord-007890-bie1veti | ( hence, if we treat alcoholic cirrhosis patients with interferon could we have a favorable response?). |
| cord-007890-bie1veti | */does its aetiology matter? |
| cord-007890-bie1veti | And on the basis of which classification system should the two legs of such a trial be separated? |
| cord-007890-bie1veti | Can coins and paper currency transmit Bacillus anthracis? |
| cord-007890-bie1veti | Can varicella be eliminated by universal childhood vaccination? |
| cord-007890-bie1veti | Do the trials with interferon alfa for patients with HBV or HCV cirrhosis exhibit a favorable result due to the antiviral properties of interferon, or is interferon exhibiting anti- oncogenic potential?, and is HCC cytokine and hormone sensitive( view ongoing trials with somatostatine analogues versus HCC)? |
| cord-007890-bie1veti | Do the trials with interferon alfa for patients with HBV or HCV cirrhosis exhibit a favorable result due to the antiviral properties of interferon, or is interferon exhibiting anti- oncogenic potential?, and is HCC cytokine and hormone sensitive( view ongoing trials with somatostatine analogues versus HCC)? |
| cord-007890-bie1veti | Does their end in the stage of cirrhosis? |
| cord-007890-bie1veti | HBV Á/ HCV and liver carcinogenesis: where does the viral influence end? |
| cord-007890-bie1veti | How ethical is it to conduct a randomised trial where one leg of cirrhotic patients is left without antiviral therapy? |
| cord-007890-bie1veti | How much hope can be put on a drug that seems to be partly useless before its initiation? |
| cord-007890-bie1veti | In vivo activity of glycopeptides against S. aureus infection in a rabbit endocarditis model: is MIC predictive for in vivo efficacy? |
| cord-007890-bie1veti | Is progression towards HCC independent of the etiology of cirrhosis( since alcoholic cirrhosis also proceeds to HCC)? |
| cord-007890-bie1veti | Lactulose, a factor that decreases endotoxaemia, in obstructive jaundice? |
| cord-007890-bie1veti | Moreover, do viral proteins with oncogenic potential exist( the controversy over the recently discovered HBV protein is still, unresolved)? |
| cord-007890-bie1veti | Our experience suggests a promising role of lamivudine in the treatment of acute hepatitis B, but how long such therapy have to be practiced and in which patients? |
| cord-007890-bie1veti | These strains was genotypically characterized for the mec A gene presence by PCR method using the mec A 1- 5?-AAA ATC CAT GGT AAA GGT TGG C-3? and the mec A 2 Á/5?-AGT TCT GCA GTA CCG GAT TTG C-3? primers( GIBCO, BRL). |
| cord-007890-bie1veti | These strains was genotypically characterized for the mec A gene presence by PCR method using the mec A 1- 5?-AAA ATC CAT GGT AAA GGT TGG C-3? and the mec A 2 Á/5?-AGT TCT GCA GTA CCG GAT TTG C-3? primers( GIBCO, BRL). |
| cord-007890-bie1veti | Which patients with HBV or HCV cirrhosis are eligible for interferon treatment? |
| cord-007890-bie1veti | and of transconjugants and the amplification by PCR of the gene aac(6?)-aph(2?? |
| cord-007890-bie1veti | and of transconjugants and the amplification by PCR of the gene aac(6?)-aph(2?? |
| cord-007890-bie1veti | can the associated morbidity and mortality in this rare but deadly disease be reduced? |
| cord-009664-kb9fnbgy | ( Symposium arranged with EFWISG) S460 MRSA in food products: cause for concern or case for complacency? |
| cord-009664-kb9fnbgy | And are we gaining or losing? |
| cord-009664-kb9fnbgy | And the equally valid question: to what extent does biological science benefit from study of fungi that are opportunistic pathogens? |
| cord-009664-kb9fnbgy | Are we aware? |
| cord-009664-kb9fnbgy | Are we in command? |
| cord-009664-kb9fnbgy | Clinical microbiology − is outsourcing the way to go? |
| cord-009664-kb9fnbgy | Do the efflux pump inhibitors reserpine and verapamil reduce the mutation frequency? |
| cord-009664-kb9fnbgy | Do we have a choice? |
| cord-009664-kb9fnbgy | Do we know where we are going? |
| cord-009664-kb9fnbgy | Do we recognise a driving force other than money? |
| cord-009664-kb9fnbgy | Does efflux phenotype impose a fitness cost? |
| cord-009664-kb9fnbgy | Emerging infections: can we cope with them? |
| cord-009664-kb9fnbgy | Furthermore, is there a pathophysiological impact of viral replication in individuals with CIHHV-6? |
| cord-009664-kb9fnbgy | If you do n't look for them, you wo n't find them: anaerobes revisited S481 Anaerobic microbiota of the mouth − friend or foe? |
| cord-009664-kb9fnbgy | Is it good, bad or just plain necessary? |
| cord-009664-kb9fnbgy | MRSA screening − will we ever agree? |
| cord-009664-kb9fnbgy | O391 Throwing caution to the winds? |
| cord-009664-kb9fnbgy | PBP 3 − SOS response? |
| cord-009664-kb9fnbgy | Patient management: the era of rapid diagnostic results( Symposium organised by Cepheid) S161 Will community MRSA and Clostridium difficile change infection control in hospitals? |
| cord-009664-kb9fnbgy | S485 Is culture still the gold standard, really? |
| cord-009664-kb9fnbgy | Should we oppose or cooperate? |
| cord-009664-kb9fnbgy | So, it is unclear how the transcription and translation of viral genes is influenced? |
| cord-009664-kb9fnbgy | The( r)evolution of clinical microbiology in Europe − is it good or bad? |
| cord-009664-kb9fnbgy | To what extent do patients benefit from translation of basic research into tools for clinical management? |
| cord-009664-kb9fnbgy | What about Europe? |
| cord-009664-kb9fnbgy | What is driving the evolution? |
| cord-009664-kb9fnbgy | or gyrA QRDR mutation frequencies than efflux negative isolates? |
| cord-009664-kb9fnbgy | which antifungal treatment for which patient? |